Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CVA21/pembrolizumab · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| CVA21/pembrolizumab | EXPERIMENTAL | CVA21/pembrolizumab |
| Name | Type | Description |
|---|---|---|
| CVA21/pembrolizumab | BIOLOGICAL | - |
Inclusion Criteria: * Histologically-confirmed (1) NSCLC, (2) bladder cancer, (3) castrate-resistant prostate cancer which are metastatic, or (4) stage 3C or stage 4 melanoma. * VLA009A: Locally advanced and/or metastatic disease for which curative surgery and/or radiation therapy is not possible a...
Top 20 of 90 competitors
CVA21/pembrolizumab is an investigational combination therapy studied in oncology. It pairs CVA21, an oncolytic virus, with pembrolizumab, a monoclonal antibody. The combination was evaluated in a Phase 1 clinical trial in patients with non-small cell lung cancer and bladder cancer. It is not an approved treatment.
CVA21/pembrolizumab was studied as a treatment for non-small cell lung cancer in a Phase 1 clinical trial. The trial also enrolled patients with bladder cancer. The combination is investigational and has not been approved for any indication.
Merck & Company, Inc. (ticker: MRK) is the developer associated with CVA21/pembrolizumab. The combination includes pembrolizumab, a Merck monoclonal antibody, and CVA21, an oncolytic virus.
CVA21/pembrolizumab is in Phase 1 clinical development. The single trial evaluating the combination has been completed. It is investigational and not approved by the FDA for any indication.
CVA21/pembrolizumab was evaluated in one clinical trial: NCT02043665, titled CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200). This Phase 1 trial enrolled 85 patients across the United States, Australia, and the United Kingdom and is completed.